Australian government recognizes value of PBS and vaccines in Federal Budget

13 May 2014
canberra-big

Following the announcement of Australia’s 2014-15 Budget today, the pharma Industry trade group Medicines Australia says it welcomes the government’s recognition of the importance of the Pharmaceutical Benefits Scheme (PBS).

“It’s encouraging to see the Australian government has been listening to the medicines industry and honored the investment in the PBS,” said Brendan Shaw, Medicines Australia chief executive, adding: “It’s pleasing that savings generated in the health portfolio will go back into medical research.”

He continued: “The new Medical Research Future Fund will be a positive step forward and we are keen to work with the government to make this research fund a reality. A medical research fund in Australia will create an environment in public and private research which can deliver the results that Australian patients deserve.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical